PURPOSE: To assess the efficacy and tolerability of chronic high-frequency deep brain stimulation (DBS) in adult patients with progressive myoclonic epilepsy (PME) syndromes. METHODS: Five adult patients (four male, 28-39 years) with PME underwent chronic high-frequency DBS according to a study protocol that had been approved by the local ethics committee. Electrodes were implanted in the substantia nigra pars reticulata (SNr)/subthalamic nucleus (STN) region in the first patient and additionally in the ventral intermediate nucleus (VIM) bilaterally in the following four cases. Follow-up took place in intervals of 3 months and DBS effects were compared with baseline frequency of passive and activation-induced myoclonic jerks and daily life performance 8 weeks prior to implantation. KEY FINDINGS: Follow-up periods ranged from 12-42 months (median 24 months). The best clinical effects were seen with SNr/STN DBS in all patients. VIM stimulation failed to achieve acute therapeutic effects and revealed low side-effect thresholds and even triggering of myoclonia. In all patients the reduction of myoclonic seizures was observed and ranged between 30% and 100% as quantified by a standardized video protocol. All patients reported clinically relevant improvements of various capabilities such as free standing and walking or improved fine motor skills. In one patient with an excellent initial response generalized tonic-clonic seizures increased after 3 months of stimulation following extensive trauma-related surgery. The best effect was seen in the least impaired patient. SIGNIFICANCE: DBS of the SNr/STN may be an effective treatment option for patients with PME. Less impaired patients may benefit more markedly. Wiley Periodicals, Inc.
PURPOSE: To assess the efficacy and tolerability of chronic high-frequency deep brain stimulation (DBS) in adult patients with progressive myoclonic epilepsy (PME) syndromes. METHODS: Five adult patients (four male, 28-39 years) with PME underwent chronic high-frequency DBS according to a study protocol that had been approved by the local ethics committee. Electrodes were implanted in the substantia nigra pars reticulata (SNr)/subthalamic nucleus (STN) region in the first patient and additionally in the ventral intermediate nucleus (VIM) bilaterally in the following four cases. Follow-up took place in intervals of 3 months and DBS effects were compared with baseline frequency of passive and activation-induced myoclonic jerks and daily life performance 8 weeks prior to implantation. KEY FINDINGS: Follow-up periods ranged from 12-42 months (median 24 months). The best clinical effects were seen with SNr/STN DBS in all patients. VIM stimulation failed to achieve acute therapeutic effects and revealed low side-effect thresholds and even triggering of myoclonia. In all patients the reduction of myoclonic seizures was observed and ranged between 30% and 100% as quantified by a standardized video protocol. All patients reported clinically relevant improvements of various capabilities such as free standing and walking or improved fine motor skills. In one patient with an excellent initial response generalized tonic-clonic seizures increased after 3 months of stimulation following extensive trauma-related surgery. The best effect was seen in the least impaired patient. SIGNIFICANCE: DBS of the SNr/STN may be an effective treatment option for patients with PME. Less impaired patients may benefit more markedly. Wiley Periodicals, Inc.
Authors: David G Anderson; Andrea H Németh; Katherine A Fawcett; David Sims; Jack Miller; Amanda Krause Journal: Mov Disord Clin Pract Date: 2016-06-16
Authors: Nathalie Van Den Berge; Daniel L Albaugh; Andrew Salzwedel; Christian Vanhove; Roel Van Holen; Wei Gao; Garret D Stuber; Yen-Yu Ian Shih Journal: Neuroimage Date: 2016-11-05 Impact factor: 6.556
Authors: Evan Wicker; Veronica C Beck; Colin Kulick-Soper; Catherine V Kulick-Soper; Safwan K Hyder; Carolina Campos-Rodriguez; Tahiyana Khan; Prosper N'Gouemo; Patrick A Forcelli Journal: Proc Natl Acad Sci U S A Date: 2019-12-16 Impact factor: 11.205